



Qutenza (capsaicin) Order Form

Patient Name: _____ DOB: _____ Male Female

Diagnosis (please provide ICD10 code) _____

Other: _____ NKDA Allergies: _____

New Start Therapy Continuation of Therapy Date of last dose (if applicable): _____

Ordering Provider: _____

Provider NPI: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Practice Contact: _____ Email (for updates): _____

QUTENZA ORDERS

DOSING:

- 1 Topical System (1 patch - 280cm² billing units)
- 2 Topical Systems (2 patches- 560cm² billing units)
- 3 Topical Systems (3 patches- 840cm² billing units)
- 4 Topical Systems (4 patches-1120cm² billing units)

LOCATION OF PATCH AND APPLICATION TIME:

- Left Foot (Dx: Diabetic Peripheral Neuropathy: 30 minute application)
- Right Foot (Dx: Diabetic Peripheral Neuropathy: 30 minute application)
- Right Side (Dx Post Herpetic Neuralgia : 60 minute application)
- Left Side (Dx Post Herpetic Neuralgia : 60 minute application)

REQUIRED TESTING/LABS:

- Clinical/Progress Notes, Labs, Tests supporting primary diagnosis (please attach)

FREQUENCY:

- Every 3 months
- Other: _____

REFILLS:

- _____
- One year from date signed

Infuse One Standing Orders:

- Provide treatment under Infuse One's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions.

Provider Name

Provider Signature

Date

Capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. Patients may experience substantial procedural pain and burning upon application of Qutenza and following removal of Qutenza. Prepare to treat acute pain during and following the application procedure with local cooling (such as an ice pack) and/or appropriate analgesic medication. Transient increases in blood pressure may occur with Qutenza treatment. Monitor blood pressure during and following the treatment procedure. Reductions in sensory function, which were generally minor and temporary, have been reported following administration of Qutenza. All patients with sensory deficits should be assessed for signs of sensory deterioration or loss prior to each application of Qutenza. If sensory loss occurs, treatment should be reconsidered.